{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:06:43Z","timestamp":1786986403556,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218518\/Z\/19\/Z"],"award-info":[{"award-number":["218518\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MR\/V011499\/1"],"award-info":[{"award-number":["MR\/V011499\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cellsig.2024.111253","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T16:48:58Z","timestamp":1717778938000},"page":"111253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["One problem, multiple potential targets: Where are we now in the development of small molecule inhibitors against Shiga toxin?"],"prefix":"10.1016","volume":"121","author":[{"given":"Samantha K.","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cellsig.2024.111253_bb0005","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/toxins2122769","article-title":"Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease","volume":"2","author":"Obrig","year":"2010","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.cellsig.2024.111253_bb0010","doi-asserted-by":"crossref","first-page":"100175","DOI":"10.1016\/j.onehlt.2020.100175","article-title":"Farm animal contact is associated with progression to Hemolytic uremic syndrome in patients with Shiga toxin-producing Escherichia coli - Indiana, 2012-2018","volume":"11","author":"Vachon","year":"2020","journal-title":"One Health"},{"key":"10.1016\/j.cellsig.2024.111253_bb0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrmicro818","article-title":"Pathogenic Escherichia coli","volume":"2","author":"Kaper","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111253_bb0020","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1128\/AAC.01661-08","article-title":"Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers","volume":"53","author":"Bitzan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017883","article-title":"Small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach","volume":"6","author":"Pang","year":"2011","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.cellsig.2024.111253_bb0030","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1017\/S0950268814003185","article-title":"An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years","volume":"143","author":"Scallan","year":"2015","journal-title":"Epidemiol Infect"},{"issue":"26","key":"10.1016\/j.cellsig.2024.111253_bb0035","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","article-title":"The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections","volume":"342","author":"Wong","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111253_bb0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41390-021-01622-3","article-title":"Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells","volume":"91","author":"S\u00e1nchez","year":"2022","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1046\/j.1365-2958.2002.02950.x","article-title":"Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli","volume":"44","author":"Wagner","year":"2002","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jmii.2016.04.006","article-title":"Regulatory elements of stx2 gene and the expression level of Shiga-like toxin 2 in Escherichia coli O157:H7","volume":"51","author":"Suardana","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1310\/hpj5203-229","volume":"52","author":"Baker","year":"2017","journal-title":"Hosp Pharm"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111253_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","article-title":"The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli","volume":"151","author":"Karmali","year":"1985","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.cellsig.2024.111253_bb0065","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1073\/pnas.84.13.4364","article-title":"Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli","volume":"84","author":"Calderwood","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0070","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0021-9258(19)75706-8","article-title":"Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1","volume":"262","author":"Lindberg","year":"1987","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0075","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/IAI.00274-13","article-title":"Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants","volume":"81","author":"Yosief","year":"2013","journal-title":"Infect Immun"},{"issue":"26","key":"10.1016\/j.cellsig.2024.111253_bb0080","doi-asserted-by":"crossref","first-page":"27511","DOI":"10.1074\/jbc.M401939200","article-title":"Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7","volume":"279","author":"Fraser","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/JCM.37.3.497-503.1999","article-title":"Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans","volume":"37","author":"Boerlin","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0090","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900439","article-title":"Tamoxifen blocks retrograde trafficking of Shiga toxin 1 and 2 and protects against lethal toxicosis","volume":"2","author":"Selyunin","year":"2019","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.cellsig.2024.111253_bb0095","author":"Centers for Disease Control and Prevention"},{"issue":"9","key":"10.1016\/j.cellsig.2024.111253_bb0100","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1021\/acs.jmedchem.1c00152","article-title":"Fighting Shigella by blocking its disease-causing toxin","volume":"64","author":"Haksar","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.cellsig.2024.111253_bb0105","doi-asserted-by":"crossref","first-page":"100299","DOI":"10.1016\/j.jbc.2021.100299","article-title":"Human Gb3\/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry","volume":"296","author":"Szymczak-Kulus","year":"2021","journal-title":"J Biol Chem"},{"issue":"5 Pt 1","key":"10.1016\/j.cellsig.2024.111253_bb0110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1203\/PDR.0b013e318211dd57","article-title":"A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of Shiga toxin 2","volume":"69","author":"Silberstein","year":"2011","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yexcr.2015.05.012","article-title":"Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells","volume":"336","author":"Tyler","year":"2015","journal-title":"Experimental Cell Research"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111253_bb0120","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/microorganisms9102157","article-title":"The Shiga toxin receptor globotriaosylceramide as therapeutic target in Shiga toxin E. coli mediated HUS","volume":"9","author":"Feitz","year":"2021","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0130","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/507705","article-title":"Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli","volume":"194","author":"Cilmi","year":"2006","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EHEC-0024-2013","article-title":"Shiga toxin (Stx) classification, structure, and function","volume":"2","author":"Melton-Celsa","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111253_bb0140","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1021\/bi971806n","article-title":"Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3","volume":"37","author":"Ling","year":"1998","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111253_bb0145","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1271\/bbb.65.414","article-title":"Inhibition of Vero cell cytotoxic activity in Escherichia coli O157:H7 lysates by globotriaosylceramide, Gb3, from bovine milk","volume":"65","author":"Watarai","year":"2001","journal-title":"Biosci Biotechnol Biochem"},{"issue":"12","key":"10.1016\/j.cellsig.2024.111253_bb0150","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1021\/acsabm.3c00919","article-title":"Gb3-coated bovine milk exosomes as a practical neutralizer for Shiga toxin","volume":"6","author":"Lu","year":"2023","journal-title":"ACS Appl Bio Mater"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0155","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/171.4.1042","article-title":"A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome","volume":"171","author":"Armstrong","year":"1995","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111253_bb0160","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111253_bb0165","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/infdis\/164.6.1160","article-title":"Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences","volume":"164","author":"Armstrong","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cellsig.2024.111253_bb0170","doi-asserted-by":"crossref","unstructured":"Kitov P.I., Sadowska J.M., Mulvey G., Armstrong G.D., Ling H., Pannu N.S., Read R.J., Bundle D.R. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature. 20000 Feb 1;403(6770):669-672. doi: 10.1038\/35001095. PMID: 10688205.","DOI":"10.1038\/35001095"},{"issue":"44","key":"10.1016\/j.cellsig.2024.111253_bb0175","doi-asserted-by":"crossref","first-page":"16837","DOI":"10.1073\/pnas.0804919105","article-title":"In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins","volume":"105","author":"Kitov","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/373996","article-title":"Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands","volume":"187","author":"Mulvey","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cellsig.2024.111253_bb0185","doi-asserted-by":"crossref","first-page":"21837","DOI":"10.1038\/srep21837","article-title":"A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-0854.2011.01319.x","article-title":"Inhibitors of intravesicular acidification protect against Shiga toxin in a pH-independent manner","volume":"13","author":"Dyve Lingelem","year":"2012","journal-title":"Traffic"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111253_bb0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/toxins13060424","article-title":"Tamoxifen derivatives alter Retromer-dependent endosomal tubulation and sorting to block retrograde trafficking of Shiga toxins","volume":"13","author":"Selyunin","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"6066","key":"10.1016\/j.cellsig.2024.111253_bb0200","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.1215930","article-title":"Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis","volume":"335","author":"Mukhopadhyay","year":"2012","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.cellsig.2024.111253_bb0205","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1091\/mbc.e13-01-0057","article-title":"Shiga toxin-binding site for host cell receptor GPP130 reveals unexpected divergence in toxin-trafficking mechanisms","volume":"24","author":"Mukhopadhyay","year":"2013","journal-title":"Mol Biol Cell"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111253_bb0210","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/toxins12050342","article-title":"Targeting the early endosome-to-Golgi transport of Shiga toxins as a therapeutic strategy","volume":"12","author":"Li","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111253_bb0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2010.01.043","article-title":"Inhibition of retrograde transport protects mice from lethal ricin challenge","volume":"141","author":"Stechmann","year":"2010","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0220","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1021\/jm4002346","article-title":"N-methyldihydroquinazolinone derivatives of Retro-2 with enhanced efficacy against Shiga toxin","volume":"56","author":"Noel","year":"2013","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41589-020-0474-4","article-title":"Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2","volume":"16","author":"Forrester","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0230","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/AAC.00455-15","article-title":"Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with Enterohemorrhagic Escherichia coli","volume":"59","author":"Secher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0235","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/ml400457j","article-title":"(S)-N-Methyldihydroquinazolinones are the active enantiomers of Retro-2 derived compounds against toxins","volume":"5","author":"Gupta","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111253_bb0240","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0092-8674(93)90638-7","article-title":"Complete vesiculation of Golgi membranes and inhibition of protein transport by a novel sea sponge metabolite, ilimaquinone","volume":"73","author":"Takizawa","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111253_bb0245","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/excr.1995.1278","article-title":"Ilimaquinone inhibits the cytotoxicities of ricin, diphtheria toxin, and other protein toxins in Vero cells","volume":"219","author":"Nambiar","year":"1995","journal-title":"Exp Cell Res"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0250","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/infdis\/171.3.721","article-title":"Inhibition of Shiga-like toxins by brefeldin A","volume":"171","author":"Donta","year":"1995","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111253_bb0255","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1083\/jcb.115.4.971","article-title":"Ricin transport in Brefeldin A-treated cells: correlation between Golgi structure and toxic effect","volume":"115","author":"Sandvig","year":"1991","journal-title":"J Cell Biol"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0260","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/glycob\/cwh085","article-title":"Brefeldin A and filipin distinguish two globotriaosyl ceramide\/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity","volume":"14","author":"Khine","year":"2004","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejmech.2009.10.007","article-title":"Simple oxidation of pyrimidinylhydrazones to triazolopyrimidines and their inhibition of Shiga toxin trafficking","volume":"45","author":"Guetzoyan","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111253_bb0270","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/BJ20080149","article-title":"The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network","volume":"414","author":"Spooner","year":"2008","journal-title":"Biochem J"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111253_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069823","article-title":"Failure of manganese to protect from Shiga toxin","volume":"8","author":"Gaston","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111253_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022713","article-title":"Eeyarestatin 1 interferes with both retrograde and anterograde intracellular trafficking pathways","volume":"6","author":"Aletrari","year":"2011","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.cellsig.2024.111253_bb0285","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1096\/fj.06-6572fje","article-title":"A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin","volume":"20","author":"Nishikawa","year":"2006","journal-title":"FASEB J"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111253_bb0290","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/protein\/5.8.775","article-title":"Analysis of several key active site residues of ricin A chain by mutagenesis and X-ray crystallography","volume":"5","author":"Kim","year":"1992","journal-title":"Protein Eng"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111253_bb0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/acsinfecdis.1c00456","article-title":"Nanobody-Based Bispecific neutralizer for Shiga toxin-producing E. coli","volume":"8","author":"Lu","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111253_bb0300","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1074\/jbc.M113.518886","article-title":"The crystal structure of Shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor","volume":"289","author":"Jacobson","year":"2014","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.cellsig.2024.111253_bb0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/toxins3091065","article-title":"Impact of the nature and size of the polymeric backbone on the ability of heterobifunctional ligands to mediate Shiga toxin and serum amyloid p component ternary complex formation","volume":"3","author":"Kitov","year":"2011","journal-title":"Toxins (Basel)"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111253_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021457","article-title":"Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2","volume":"6","author":"Griener","year":"2011","journal-title":"PLoS One"},{"issue":"11\u201312","key":"10.1016\/j.cellsig.2024.111253_bb0315","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0041-0101(96)00103-1","article-title":"Structural analysis of ricin and implications for inhibitor design","volume":"34","author":"Robertus","year":"1996","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0320","doi-asserted-by":"crossref","first-page":"11443","DOI":"10.1038\/s41598-022-15316-1","article-title":"A unique peptide-based pharmacophore identifies an inhibitory compound against the A-subunit of Shiga toxin","volume":"12","author":"Watanabe-Takahashi","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111253_bb0325","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/jm010186s","article-title":"Structure-based design and characterization of novel platforms for ricin and Shiga toxin inhibition","volume":"45","author":"Miller","year":"2002","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111253_bb0330","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1006\/jmbi.1996.0865","article-title":"Structure-based identification of a ricin inhibitor","volume":"266","author":"Yan","year":"1997","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.cellsig.2024.111253_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277770","article-title":"Pterin-based small molecule inhibitor capable of binding to the secondary pocket in the active site of ricin-toxin A chain","volume":"17","author":"Saito","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111253_bb0340","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1021\/acsinfecdis.0c00127","article-title":"Small Molecule Inhibitors Targeting the Interaction of Ricin Toxin A Subunit with Ribosomes","volume":"6","author":"Li","year":"2020","journal-title":"ACS Infect Dis."},{"issue":"12","key":"10.1016\/j.cellsig.2024.111253_bb0345","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/nar\/28.12.2383","article-title":"4-Aminopyrazolo[3,4-d]pyrimidine (4-APP) as a novel inhibitor of the RNA and DNA depurination induced by Shiga toxin 1","volume":"28","author":"Brigotti","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cellsig.2024.111253_bb0350","doi-asserted-by":"crossref","first-page":"825856","DOI":"10.3389\/fcimb.2022.825856","article-title":"Therapeutic antibodies against Shiga toxins: Trends and perspectives","volume":"12","author":"Henrique","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"32","key":"10.1016\/j.cellsig.2024.111253_bb0355","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/j.vaccine.2013.05.013","article-title":"Advances in the development of Enterohemorrhagic Escherichia coli vaccines using murine models of infection","volume":"31","author":"Garcia-Angulo","year":"2013","journal-title":"Vaccine"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824002213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824002213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T01:46:34Z","timestamp":1744249594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656824002213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":71,"alternative-id":["S0898656824002213"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111253","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One problem, multiple potential targets: Where are we now in the development of small molecule inhibitors against Shiga toxin?","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111253"}}